342 related articles for article (PubMed ID: 30870485)
61. Enhanced effects of xanthohumol plus honokiol on apoptosis in 3T3-L1 adipocytes.
Yang JY; Della-Fera MA; Rayalam S; Baile CA
Obesity (Silver Spring); 2008 Jun; 16(6):1232-8. PubMed ID: 18369342
[TBL] [Abstract][Full Text] [Related]
62. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
63. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
Odoux C; Albers A; Amoscato AA; Lotze MT; Wong MK
Int J Cancer; 2002 Feb; 97(4):458-65. PubMed ID: 11802207
[TBL] [Abstract][Full Text] [Related]
64. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.
Belyanskaya LL; Ziogas A; Hopkins-Donaldson S; Kurtz S; Simon HU; Stahel R; Zangemeister-Wittke U
Lung Cancer; 2008 Jun; 60(3):355-65. PubMed ID: 18093694
[TBL] [Abstract][Full Text] [Related]
65. Glutamine deprivation sensitizes human breast cancer MDA-MB-231 cells to TRIAL-mediated apoptosis.
Dilshara MG; Jeong JW; Prasad Tharanga Jayasooriya RG; Neelaka Molagoda IM; Lee S; Park SR; Choi YH; Kim GY
Biochem Biophys Res Commun; 2017 Apr; 485(2):440-445. PubMed ID: 28202415
[TBL] [Abstract][Full Text] [Related]
66. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
67. Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells.
Portanova P; Notaro A; Pellerito O; Sabella S; Giuliano M; Calvaruso G
Int J Oncol; 2013 Jul; 43(1):121-30. PubMed ID: 23686163
[TBL] [Abstract][Full Text] [Related]
68. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation.
Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y
Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955
[TBL] [Abstract][Full Text] [Related]
69. Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway.
Zhu W; Zhan D; Wang L; Ma D; Cheng M; Wang H; Zhao J; Cai Y; Cheng Z
Oncol Rep; 2016 Aug; 36(2):845-52. PubMed ID: 27277541
[TBL] [Abstract][Full Text] [Related]
70. Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation.
Chen L; Hao M; Yan J; Sun L; Tai G; Cheng H; Zhou Y
J Biol Chem; 2021; 296():100515. PubMed ID: 33676890
[TBL] [Abstract][Full Text] [Related]
71. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors.
Shenoy K; Wu Y; Pervaiz S
Cancer Res; 2009 Mar; 69(5):1941-50. PubMed ID: 19223550
[TBL] [Abstract][Full Text] [Related]
72. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells.
Park KJ; Lee SH; Kim TI; Lee HW; Lee CH; Kim EH; Jang JY; Choi KS; Kwon MH; Kim YS
Cancer Res; 2007 Aug; 67(15):7327-34. PubMed ID: 17671202
[TBL] [Abstract][Full Text] [Related]
73. Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2.
Yang ES; Woo SM; Choi KS; Kwon TK
Exp Cell Res; 2011 Nov; 317(18):2592-601. PubMed ID: 21854768
[TBL] [Abstract][Full Text] [Related]
74. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
75. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
[TBL] [Abstract][Full Text] [Related]
76. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
Horinaka M; Yoshida T; Nakata S; Shiraishi T; Tomosugi M; Yoshikawa S; Wakada M; Sakai T
Cancer Sci; 2012 Feb; 103(2):282-7. PubMed ID: 22077238
[TBL] [Abstract][Full Text] [Related]
77. Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks.
Bertram H; Nerlich A; Omlor G; Geiger F; Zimmermann G; Fellenberg J
Mod Pathol; 2009 Jul; 22(7):895-905. PubMed ID: 19305384
[TBL] [Abstract][Full Text] [Related]
78. Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
Sun T; Zhu T; Liang X; Yang S; Zhao R
Med Sci Monit; 2018 Apr; 24():2550-2561. PubMed ID: 29695684
[TBL] [Abstract][Full Text] [Related]
79. Irigenin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells.
Xu Y; Gao CC; Pan ZG; Zhou CW
Biochem Biophys Res Commun; 2018 Feb; 496(3):998-1005. PubMed ID: 29305260
[TBL] [Abstract][Full Text] [Related]
80. Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5.
Li Y; Fan X; Goodwin CR; Laterra J; Xia S
BMC Cancer; 2008 Nov; 8():325. PubMed ID: 18992144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
